Therapy News and Research

RSS

Overtesting for HbA1C levels can increase risk of severe hypoglycemia

With a more-is-better mindset common in society, frequent commercials encouraging checks of glycated hemoglobin (HbA1C) levels, and ads for new diabetes medications to lower HbA1C in adults with Type 2 diabetes, Mayo Clinic researchers were not too surprised to find overtesting occurring.

7 Jun 2016

Coagadex now available for rare bleeding disorder patients in the UK

Bio Products Laboratory, Limited (BPL) today announced that Coagadex is now available for patients in the UK.

7 Jun 2016

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute.

7 Jun 2016

New systems-based strategy may help accelerate TB drug discovery

The rise in multi-drug resistant (MDR) and extremely drug resistant (XDR) strains of Mycobacterium tuberculosis (MTB) is becoming a major cause of global health concern for treating tuberculosis, which affects a third of the global population.

7 Jun 2016

Study shows aggressive end-of-life care for young cancer patients may be less effective

In the last month of their lives, younger cancer patients continued to be hospitalized and receive other aggressive treatment at high rates, a University of North Carolina Lineberger Comprehensive Cancer Center-led study found.

7 Jun 2016

Combination immunotherapy may be better than one to combat metastatic melanoma

A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one.

7 Jun 2016

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.

7 Jun 2016

Unlocking the first gene to cause otosclerosis: an interview with Dr Ralph Holme

Otosclerosis is a common cause of hearing loss, particularly amongst young adults. It normally starts in their 20s or 30s and it affects about 1 in 200 hundred people. In the UK, about 300,000 people are affected by the condition.

7 Jun 2016

HKUST study suggests innate immune response plays vital role in pathogenesis of AD

Alzheimer's disease (AD) is a devastating condition with no known effective treatment. The disease is characterized by memory loss as well as impaired locomotor ability, reasoning, and judgment. Emerging evidence suggests that the innate immune response plays a major role in the pathogenesis of AD.

7 Jun 2016

Taking hormone therapy drugs for additional five years improves outcomes in breast cancer patients

Breast cancer patients significantly benefit by taking hormone therapy drugs called aromatase inhibitors for an additional five years, according to a major study presented at the Plenary Session of the American Society of Clinical Oncology annual meeting in Chicago and published in the New England Journal of Medicine.

7 Jun 2016

Genes of healthy leanness could lead to new approach to treating obesity-related diabetes

People with type 2 diabetes could be helped by the discovery of a gene linked to leanness.

7 Jun 2016

$One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture$

One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture

More than 53 million Americans age 50 and older, primarily women, have osteoporosis or are at high risk for the condition due to low bone density. A recent study of oral bisphosphonates, the most commonly prescribed osteoporosis treatment, found that approximately a third of women prescribed these drugs continue to be at elevated risk for bone fracture, an outcome that may have several origins.

7 Jun 2016

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization and related skills as long-term survivors.

7 Jun 2016

Financial pressures prevent access to much-needed care for cancer patients

Financial pressures kept cancer patients from filling prescription medications and attending their doctors' visits, University of North Carolina Lineberger Comprehensive Cancer Center researchers found in a new study.

6 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

A new University of Leicester study has confirmed the therapeutic potential of bacteriophage combinations to treat highly infectious bacteria C. difficile infections (CDI) while retaining a healthy gut.

6 Jun 2016

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

6 Jun 2016

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Empagliflozin has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

6 Jun 2016

Cobimetinib combined with vemurafenib shows added benefit for melanoma with BRAF V600 mutation

Cobimetinib has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation.

6 Jun 2016

New study finds alternative approaches to target proteins sustaining cancer, Alzheimer's disease

Drugs to treat cancer and Alzheimer's disease usually target the active sites of specific protein molecules sustaining the disease. Traditional drug design views proteins as rigid 3-D objects with active sites consisting of surface-accessible "pockets" with a specific, well-defined structure.

6 Jun 2016

Therapy News and Research

Overtesting for HbA1C levels can increase risk of severe hypoglycemia

Coagadex now available for rare bleeding disorder patients in the UK

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

New systems-based strategy may help accelerate TB drug discovery

Study shows aggressive end-of-life care for young cancer patients may be less effective

Combination immunotherapy may be better than one to combat metastatic melanoma

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Unlocking the first gene to cause otosclerosis: an interview with Dr Ralph Holme

HKUST study suggests innate immune response plays vital role in pathogenesis of AD

Taking hormone therapy drugs for additional five years improves outcomes in breast cancer patients

Genes of healthy leanness could lead to new approach to treating obesity-related diabetes

One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Financial pressures prevent access to much-needed care for cancer patients

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Cobimetinib combined with vemurafenib shows added benefit for melanoma with BRAF V600 mutation

New study finds alternative approaches to target proteins sustaining cancer, Alzheimer's disease

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News